by newerapr | Sep 5, 2019 | Press Release
Dynabook Americas, Inc., Inc. (formerly Toshiba America Client Solutions, Inc.), today announced the Tecra® X50, the brand’s thinnest and lightest full-featured 15.6-inch laptop. The addition of the newly designed Tecra® X50 rounds out the Dynabook portfolio of award-winning, high-performance X Series laptops, which includes 12-, 13- and 14-inch models. “With the Tecra X50, Dynabook has changed the expectation of the desktop replacement computer in terms of weight, design and performance by delivering a laptop loaded with heavy-hitting features in an ultra-thin form factor,” said Philip Osako, vice president, marketing and engineering, Dynabook Americas, Inc. “The Tecra X50 is the perfect complement to our portfolio of premium professional-grade laptops.”
With a starting weight of 3.13 pounds1 and measuring just 0.69 inches (17.6 mm) thin, the Tecra X50 is the thinnest and lightest 15.6-inch premium laptop Dynabook has ever created. The laptop boasts an ultra-lightweight ToughBody magnesium alloy chassis in Onyx Blue – 40 percent lighter than plastic – and a Honeycomb Rib Structure, to provide extra durability. Dynabook engineered the Tecra X50 to US Military (MIL-STD-810G) standard by having the laptop undergo military-grade drop, temperature, humidity and dustproof testing to demonstrate its overall robustness.
In addition to its compact design, the laptop has a battery life rating of up to 17 hours2 on a single charge. To achieve this extended battery life, the Tecra X50 incorporates an IGZO LCD screen, developed by Sharp that consumes half the power of a standard LCD screen without compromising on brightness. This energy efficient display technology, coupled with the impressive battery life rating, means that mobile professionals will not need to worry about power while working remotely. Dynabook will offer configurations of the Tecra X50 with either Full HD or Full HD with Touch3 display options.
As the newest addition to the Dynabook premium, laptop collection, the Tecra X50 laptop includes a variety of advancements in processor, connectivity, instant on/off and cooling technologies. Developed to address the needs of business and education users, the Tecra X50 is powered by the latest 8th Generation Intel® Core™ vPro™ processors for improved performance and connectivity speeds.
The Tecra X50 adheres to the new IEEE 802.11ax4 standard making the new laptop a Wi-Fi® 6 device capable of operating in both the 2.4 and 5 GHz bands. This next-generation Wi-Fi standard provides higher capacity, coverage and improves performance, even in congested environments with many connected devices such as conference halls and other public venues.
As a Modern PC, the Tecra X50 maximizes the instant on/off capabilities of Windows 10 Modern Standby. This unique feature allows optimized software and applications on the Tecra X50 to stay up-to-date by maintaining a low-power connection to an available network (Wi-Fi or wired Ethernet) and run background processes while the laptop is in sleep mode. The ability to remain always on and connected to the Internet, ensures a user’s email, calendar and notifications are current. Not only does this feature boost system wake and resume times, it also makes the laptop more energy efficient.
To support the new performance features of the Tecra X50, Dynabook enhanced the fan technology for improved airflow and cooling by increasing the volume of air by 10 percent when compared to the Tecra Z50. Called an S-Type fan, this cooling design improvement delivers a quieter running system especially when running processor-intensive tasks.
Dynabook armed the Tecra X50 with advanced security elements including the company’s proprietary BIOS, TPM 2.0 and optional smart card reader. The laptop is configured with two biometrics technologies an integrated IR camera for face authentication and a Synaptics’ TouchPad SecurePad™ with integrated fingerprint reader. A unique security measure found on the Tecra X50 that addresses the growing awareness of webcam security is the adoption of a new webcam shutter slider that increases user privacy.
To expand the overall functionality of the laptop in terms of data, display and power, the Tecra X50 includes two USB-C ports with Thunderbolt 3 support, as well as two USB 3.1 Gen 1 ports. These ports pair perfectly with the Thunderbolt™ 3 Dock and newly announced Dynabook USB-C™ Dock.
The Dynabook Tecra X50 laptop will be available at us.dynabook.com, from the company’s network of resellers and part of the organization’s Build-to-Order (BTO) program, giving users the ability to customize memory, storage, display and security capability options. All Dynabook laptops, including the Tecra X50, are designed, engineered and rigorously tested in dedicated Dynabook facilities to deliver greater peace of mind and proven reliability.
The Tecra X50 will include the company’s standard international three-year limited warranty program. Pricing for the Tecra X50 will start at $1,544 (MSRP).
by newerapr | Sep 5, 2019 | Press Release
VetCell Therapeutics USA showcases the latest veterinary cell therapy technologies
VetCell Therapeutics USA
, a pet-focused cell therapy division of PrimeGen Global, Inc.
, announced today that the company will be presenting multiple presentations at the North American Veterinary Regenerative Medicine Association’s (NAVRMA) annual conference, taking place September 8 – 11, 2019 in Niagara-on-the-Lake, Ontario at the Queen’s Landing Hotel.
Dr. Chad Maki, chief medical officer at VetCell Therapeutics USA, will deliver two oral presentations on September 9, 2019:
10:45 AM – 11:00 AM
: Title: A Novel, Proprietary Intravenous Delivery Solution Sustains Feline Adipose-Derived Mesenchymal Stem Cell Viability and Function for 7 Days at Cold Temperature.
During this presentation, Dr. Maki will unveil a new stem cell shipping solution designed to keep cells fresh during shipping for up to a week.
11:30 AM – 11:45 AM
: Title: Intra-articular Administration of Allogeneic Adipose Derived MSCs Reduces Pain and Lameness in Dogs with Hip Osteoarthritis: A Multicentered, Double Blinded, Randomized, Placebo Controlled Pilot Study
. During this presentation, Dr. Maki will reveal the results from its clinical trial focused on treating canine osteoarthritis with allogeneic mesenchymal stem cells (MSCs). This trial was coordinated in Hong Kong by VetCell Therapeutics Asia
under the leadership and supervision of the company’s CEO Dr. Raymond Tong.
In addition, VetCell Therapeutics USA will present a poster titled, Manufacturing of Allogeneic Feline Adipose Mesenchymal Stem Cells for Clinical Applications. This poster summarizes VetCell Therapeutics USA’s development of a comprehensive procedure for the production of large batches of allogeneic feline Mesenchymal Stem Cells (MSCs) in a consistent and controlled setting. This controlled process results in a high-quality cell product suited for clinical research or testing in a variety of disease models. It also serves as the foundation for its global business activities with VetCell Therapeutics Asia.
“The field of regenerative medicine relies heavily on the characteristics and quality measures of the cell product being utilized. The production of a predictable, consistent high-quality cell therapy product in accordance with GMP guidelines is crucial, as is the shipping methods used for ensuring that cell products arrive at veterinary offices with consistent and reliable maximum quality. This year at NAVRMA, we’re excited to showcase our latest breakthroughs in allogeneic MSC therapy production, cell therapy shipping innovations and exciting results from our own clinical studies,” said Dr. Maki.
To learn more about VetCell Therapeutics USA, please visit www.vetcelltherapeuticsusa.com.
About VetCell Therapeutics USA:
VetCell Therapeutics’ mission is to develop the highest-quality cell-based therapies for ailing pet companions to improve their quality of life. VetCell Therapeutics USA recognizes that cell-based therapies are becoming commonplace and have been shown to effectively improve the wellbeing of pets and humans alike. The company is focused on developing and commercializing novel and innovative stem cell therapies for unmet medical needs for companion pets globally. The scientific efforts conducted by VetCell Therapeutics USA, VetCell Therapeutics Asia and its parent company PrimeGen Global, Inc. are translational across many animal species and will help to provide a solid foundation for future human stem cell therapies. VetCell Therapeutics USA and VetCell Therapeutics Asia are independently operated divisions of PrimeGen Global, Inc. focused on developing and manufacturing cell therapies for veterinary applications.
About PrimeGen Global, Inc.:
PrimeGen Global, Inc. (PrimeGen) is a pioneer in researching and developing clinical applications for stem cells in human medicine. With industry expertise spanning two decades, PrimeGen is on a mission to deliver on the promise of cellular treatments through patented technology that activates Mesenchymal Stem Cells (MSCs) to target and influence the inflammatory process – the root of most diseases.